Special Issue

Rational Vaccine Design against Malaria

Message from the Guest Editors

Malaria remains one of the most devastating and lifethreatening diseases worldwide that causes more than half a million deaths annually. The currently available malaria vaccine, RTS,S/ASO1, can prevent malaria in voung African children noting a 30% reduction in deadly severe anemia. However, higher vaccine efficacy is much needed. Therefore, it is necessary to identify potential vaccine candidates to elicit more robust protective responses against malaria. In light of malaria parasites' available genomic, proteomic, and metabolomic information, it is the most promising time to switch from traditional empirical approaches to advanced, rational designs, and to identify potent malaria vaccine candidates. We are pleased to invite you to submit your manuscript related to novel strategies for malaria vaccine design. We welcome original research articles describing novel malaria vaccine candidates based on (but not limited to) parasite-focused and reverse vaccinology, structural vaccinology, and/or immunoinformatics.

Guest Editors

Dr. Hirdesh Kumar

Dr. Peeyush Ranjan

Dr. Vinav Kumar

Dr. Sarita Puri Mishra

Deadline for manuscript submissions

closed (31 December 2022)



an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/114673

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines





an Open Access Journal by MDPI

Impact Factor 3.4 CiteScore 9.9 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).

